If you read their footnotes, they say:
"In total, 95,223 (61.93%) participants in COVID-19 group received COVID-19 vaccine (42,065 (44.18%), 45,450 (47.73%) and 7708 (8.09%) received BNT162b2, mRNA-1273 and Ad26.COV2.S, respectively) and 3,173,169 (56.29%) participants in contemporary group received COVID-19 vaccine (1,349,844 (42.54%), 1,609,399 (50.72%) and 213,926 (6.74%) received BNT162b2, mRNA-1273 and Ad26.COV2.S, respectively) before end of follow up."
So it looks like both the COVID-19 group and contemporary group had received the covid vaccine.
If you read their footnotes, they say: "In total, 95,223 (61.93%) participants in COVID-19 group received COVID-19 vaccine (42,065 (44.18%), 45,450 (47.73%) and 7708 (8.09%) received BNT162b2, mRNA-1273 and Ad26.COV2.S, respectively) and 3,173,169 (56.29%) participants in contemporary group received COVID-19 vaccine (1,349,844 (42.54%), 1,609,399 (50.72%) and 213,926 (6.74%) received BNT162b2, mRNA-1273 and Ad26.COV2.S, respectively) before end of follow up."
So it looks like both the COVID-19 group and contemporary group had received the covid vaccine.